Company intelligence / Profile preview

Small Pharma

London, England, United Kingdomuk.linkedin.com ↗

Ownership: Private
Employees: ~30
Development stage: Phase 2

Overview

Small Pharma is a clinical-stage biotechnology company developing psychedelic-based treatments for mental health disorders, with its lead candidate SPL026 (N,N-dimethyltryptamine, DMT) having completed a Phase IIa trial demonstrating rapid and durable antidepressant effects in patients with major depressive disorder. The company has also advanced other short-duration psychedelic compounds into early clinical development.

Therapeutic areas: Psychiatry
Modalities: Small moleculesPsychedelic-assisted therapies (notably DMT and related compounds)
Industry: Biotech

Drug pipeline

2 assets

DMT

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Small Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Small Pharma.

Explore the full profile